<br>        Inclusion Criteria<br><br>          -  Patient with follicular lymphoma grade 1 - 2<br><br>          -  Refractory to rituximab given as monotherapy or in combination with any chemotherapy<br>             or to rituximab given as maintenance treatment following R-chemo, defined as:<br><br>          -  failure to achieve at least PR to rituximab given as monotherapy or in combination<br>             with any chemotherapy; or,<br><br>          -  disease progression while on rituximab (either given as monotherapy or in combination<br>             with any chemotherapy or during rituximab maintenance treatment following R-chemo);<br>             or,<br><br>          -  disease progression in responders within 6 months of the last dose of rituximab<br>             (either given as monotherapy or in combination with any chemotherapy or after<br>             rituximab maintenance treatment schedule following R-chemo)<br><br>          -  Tumor verified to be CD20+ positive from excisional lymph node biopsy<br><br>          -  CT scan in screening phase (based on local evaluation) showing:<br><br>          -  2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or<br><br>          -  1 clearly demarcated lesion with a largest diameter = 2,0 cm<br><br>          -  ECOG Performance Status of 0, 1, or 2<br><br>          -  Age = 18 years<br><br>          -  Following receipt of verbal and written information about the study, the patient must<br>             provide signed informed consent before any study related activity is carried out<br><br>        Exclusion Criteria<br><br>          -  Previous autologous stem cell transplantation within 6 months<br><br>          -  Previous allogeneic stem cell transplantation<br><br>          -  More than 1 previous radio immunotherapy regimen<br><br>          -  Received radio immunotherapy within 3 months<br><br>          -  Received any Anti-cancer treatment within 4 weeks<br><br>          -  Received monoclonal antibodies, other than rituximab within 3 months<br><br>          -  Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab<br><br>          -  Life expectancy less than 6 months<br>      ;<br>        Inclusion Criteria<br><br>          -  Patient with follicular lymphoma grade 1 - 2<br><br>          -  Refractory to rituximab given as monotherapy or in combination with any chemotherapy<br>             or to rituximab given as maintenance treatment following R-chemo, defined as:<br><br>          -  failure to achieve at least PR to rituximab given as monotherapy or in combination<br>             with any chemotherapy; or,<br><br>          -  disease progression while on rituximab (either given as monotherapy or in combination<br>             with any chemotherapy or during rituximab maintenance treatment following R-chemo);<br>             or,<br><br>          -  disease progression in responders within 6 months of the last dose of rituximab<br>             (either given as monotherapy or in combination with any chemotherapy or after<br>             rituximab maintenance treatment schedule following R-chemo)<br><br>          -  Tumor verified to be CD20+ positive from excisional lymph node biopsy<br><br>          -  CT scan in screening phase (based on local evaluation) showing:<br><br>          -  2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or<br><br>          -  1 clearly demarcated lesion with a largest diameter = 2,0 cm<br><br>          -  ECOG Performance Status of 0, 1, or 2<br><br>          -  Age = 18 years<br><br>          -  Following receipt of verbal and written information about the study, the patient must<br>             provide signed informed consent before any study related activity is carried out<br><br>        Exclusion Criteria<br><br>          -  Previous autologous stem cell transplantation within 6 months<br><br>          -  Previous allogeneic stem cell transplantation<br><br>          -  More than 1 previous radio immunotherapy regimen<br><br>          -  Received radio immunotherapy within 3 months<br><br>          -  Received any Anti-cancer treatment within 4 weeks<br><br>          -  Received monoclonal antibodies, other than rituximab within 3 months<br><br>          -  Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab<br><br>          -  Life expectancy less than 6 months<br>      ;<br>        Inclusion Criteria<br><br>          -  Patient with follicular lymphoma grade 1 - 2<br><br>          -  Refractory to rituximab given as monotherapy or in combination with any chemotherapy<br>             or to rituximab given as maintenance treatment following R-chemo, defined as:<br><br>          -  failure to achieve at least PR to rituximab given as monotherapy or in combination<br>             with any chemotherapy; or,<br><br>          -  disease progression while on rituximab (either given as monotherapy or in combination<br>             with any chemotherapy or during rituximab maintenance treatment following R-chemo);<br>             or,<br><br>          -  disease progression in responders within 6 months of the last dose of rituximab<br>             (either given as monotherapy or in combination with any chemotherapy or after<br>             rituximab maintenance treatment schedule following R-chemo)<br><br>          -  Tumor verified to be CD20+ positive from excisional lymph node biopsy<br><br>          -  CT scan in screening phase (based on local evaluation) showing:<br><br>          -  2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or<br><br>          -  1 clearly demarcated lesion with a largest diameter = 2,0 cm<br><br>          -  ECOG Performance Status of 0, 1, or 2<br><br>          -  Age = 18 years<br><br>          -  Following receipt of verbal and written information about the study, the patient must<br>             provide signed informed consent before any study related activity is carried out<br><br>        Exclusion Criteria<br><br>          -  Previous autologous stem cell transplantation within 6 months<br><br>          -  Previous allogeneic stem cell transplantation<br><br>          -  More than 1 previous radio immunotherapy regimen<br><br>          -  Received radio immunotherapy within 3 months<br><br>          -  Received any Anti-cancer treatment within 4 weeks<br><br>          -  Received monoclonal antibodies, other than rituximab within 3 months<br><br>          -  Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab<br><br>          -  Life expectancy less than 6 months<br>      ;<br>        Inclusion Criteria<br><br>          -  Patient with follicular lymphoma grade 1 - 2<br><br>          -  Refractory to rituximab given as monotherapy or in combination with any chemotherapy<br>             or to rituximab given as maintenance treatment following R-chemo, defined as:<br><br>          -  failure to achieve at least PR to rituximab given as monotherapy or in combination<br>             with any chemotherapy; or,<br><br>          -  disease progression while on rituximab (either given as monotherapy or in combination<br>             with any chemotherapy or during rituximab maintenance treatment following R-chemo);<br>             or,<br><br>          -  disease progression in responders within 6 months of the last dose of rituximab<br>             (either given as monotherapy or in combination with any chemotherapy or after<br>             rituximab maintenance treatment schedule following R-chemo)<br><br>          -  Tumor verified to be CD20+ positive from excisional lymph node biopsy<br><br>          -  CT scan in screening phase (based on local evaluation) showing:<br><br>          -  2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or<br><br>          -  1 clearly demarcated lesion with a largest diameter = 2,0 cm<br><br>          -  ECOG Performance Status of 0, 1, or 2<br><br>          -  Age = 18 years<br><br>          -  Following receipt of verbal and written information about the study, the patient must<br>             provide signed informed consent before any study related activity is carried out<br><br>        Exclusion Criteria<br><br>          -  Previous autologous stem cell transplantation within 6 months<br><br>          -  Previous allogeneic stem cell transplantation<br><br>          -  More than 1 previous radio immunotherapy regimen<br><br>          -  Received radio immunotherapy within 3 months<br><br>          -  Received any Anti-cancer treatment within 4 weeks<br><br>          -  Received monoclonal antibodies, other than rituximab within 3 months<br><br>          -  Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab<br><br>          -  Life expectancy less than 6 months<br>